Polycyclic aromatic hydrocarbons (PAHs) are high-priority environmental contaminants because of their toxic, carcinogenic, and putative estrogenic or antiestrogenic properties in the human body. Human exposure to highmolecular-weight PAHs mainly occurs through oral uptake of charcoal-broiled, grilled, and smoked meats (van Maanen et al. 1994 ) and through ingestion of soil or poorly cleaned vegetables, resulting in exposed doses about an order of magnitude higher than exposure by inhalation (Heisterkamp and van Veen 1997) . The hazardous effects of ingested PAHs come from the PAH fraction released from the nutrients, soil, or associated organic matter in the intestinal lumen and that, upon intestinal absorption, reaches the intestine enterocytes and liver hepatocytes. In these cells, PAHs may act as ligands to the human aryl hydrocarbon (Ah) receptor, which plays a central role in the toxic response of specific aromatic hydrocarbons by the regulation of typical human biotransformation enzymes (reviewed by Hankinson 1995) .
The risk from orally ingested PAHs is currently thought to be reduced when co-ingested soil or fibers decrease the intestinal PAH absorption and hence bioavailability (De Kok and van Maanen 2000) . Most ingested PAHs pass harmlessly through the gastrointestinal (GI) tract without being transformed by human enzymes to hazardous metabolites. However, this assumes that no microbial biotransformation of PAHs occurs. The human GI tract harbors an incredibly diverse microbial community, which typically performs fermentative processes but which is also capable of transforming xenobiotic compounds (Aura et al. 2002; Ilett et al. 1990; Macdonald et al. 1983) . Hence, if microbial PAH biotransformation in the human colon is possible, the susceptibility of the colon epithelium to bioactive PAH metabolites may increase the health risks that are associated with nonabsorbed PAHs that reach the colon. To date, no information is available on the PAH bioactivation potency from human colon microbiota. To evaluate this, in this study we investigated the estrogenicity of PAHs because several PAH metabolites structurally resemble steroidal hormones that bind the human estrogen receptor (ER) (Ariese et al. 2001) , which could thus lead to estrogenic or antiestrogenic activity in vivo.
We opted for an in vitro approach to specifically look for microbial biotransformations and thus avoid possible interference from colon epithelium enzymes that would be present in an in vivo approach. Pure PAH compounds and a PAH-contaminated urban soil were incubated in the stomach, small intestine, and colon suspensions from a simulator of the human GI tract. Given the aromaticity of PAHs, we used a modified Ah receptor yeast assay (Miller 1997 ) to investigate whether the PAHs in the different digests could activate the human Ah receptor and subsequently induce signal transduction. We also investigated the estrogenicity of the PAH incubated digests by monitoring activation of the human ER in a modified ER yeast assay (Routledge and Sumpter 1996) . In addition, we applied a newly optimized liquid chromatography-mass spectrometry (LC-MS) protocol to detect whether PAH metabolites were formed during incubation.
Materials and Methods
Chemicals. PAH parent compounds naphthalene, phenanthrene, pyrene, and benzo(a)pyrene (reagent grade) were obtained from SigmaAldrich (Bornem, Belgium). To avoid solubility problems in the incubation tests, PAHs were first dissolved in ethanol before digestion. All stock solutions were prepared in amber glass bottles and stored in the dark at 4°C. Hydroxy-PAH metabolites 1-OH naphthalene, 9-OH phenanthrene, 1-OH pyrene, and 7-OH benzo(a)pyrene were reagent grade and also obtained from Sigma-Aldrich.
Incubations. PAHs and soils were incubated in batches by sampling GI suspensions from a simulator of the human intestinal microbial ecosystem (SHIME). This dynamic model of the GI tract consists of five compartments representing the stomach, small intestine, and colon ascendens, transversum, and descendens (Figure 1 ). The colon suspension contains in vitro cultured microbiota that were isolated from human feces and are representative of the in vivo colon microbial ecology after a growth stabilization period in the different colon compartments (Molly et al. 1993) . A typical stomach digestion consists of an incubation of PAHs or PAH-contaminated soil samples for 3 hr at pH 1.5 at 37°C. A small intestine digestion consists of an incubation for 5 hr at pH 7 at 37°C in the presence of bile salts (0.2 mmol/L) and pancreatic enzymes supplemented as pancreatic powder of porcine origin (0.4 g/L). A colon digestion consists of an incubation with colon microbiota for 48 hr at 37°C, withdrawn from the colon vessels of the SHIME reactor. Some samples were incubated with inactive colon microbiota. For this, colon microbiota were autoclaved for 30 min (121°C, 1 bar overpressure). Incubation of PAH standard compounds in stomach, small intestine, and colon digests occurred at a concentration of 20 µmol/L. This concentration is normally not encountered in the GI tract but gave us more possibilities to study microbial PAH metabolism in depth. GI digestion experiments on soil samples were performed as previously described (Van de Wiele et al. 2004b ) to simulate a hypothetical soil ingestion of 5 g/day by pica-afflicted children (stomach, 40 mL; small intestine, 60 mL; colon, 100 mL). To avoid photocatalytic effects, all digestions were performed in amber flasks. After the respective incubations, samples were centrifuged at 3,000g for 10 min to remove most of the particulates and biomass. The supernatants were then stored at -20°C before analysis.
Sample treatment. PAH parent components and PAH metabolites were extracted from the digests by performing a liquid/liquid extraction in which the digest and ethyl acetate were mixed in a 1:1 ratio. The ethyl acetate fraction was then put in a rotary evaporator to remove most of the solvent. The remainder of the solvent was removed under a gentle stream of nitrogen gas and finally replaced by dimethyl sulfoxide, which is suitable for use in bioassay tests. For chemical analysis of the samples using LC-MS, sample aliquots were subjected to solid-phase extraction using PrepSep C 18 (250 mg; Fisher Scientific, Edmonton, Alberta, Canada). Hydroxy-PAHs were eluted with methanol.
PAH conjugate analysis. To check whether conjugated PAH metabolites were formed in the different digests, samples were also incubated in the presence of β-glucuronidase and aryl sulfatase, both obtained from SigmaAldrich. After the PAH parent compounds had been incubated in SHIME suspension, a 1 mL aliquot of these samples was diluted in 1 mL 0.1 M acetate buffer, and the pH was adjusted to 5 with sodium hydroxide. A volume of 400 µL β-glucuronidase (100 U/mL) and 250 µL aryl sulfatase (60 U/mL) was added, and the mixture was incubated for 6 hr at 37°C to hydrolyze the PAH conjugates.
Bioassays. For the bioassays, we used a modified protocol from De Boever et al. (2001) that was based on the protocol developed by Routledge and Sumpter (1996) for the yeast estrogen bioassay and Miller (1997) for the yeast Ah bioassay. Briefly, these researchers transformed Saccharomyces cerevisiae with the human Ah receptor gene and the human ER-α gene, together with expression plasmids containing responsive elements and the lacZ reporter gene (encoding the enzyme β-galactosidase). The expression of β-galactosidase is triggered by test chemicals, which upon binding to the respective receptors induce the conformational change necessary for binding of the receptor/ligand dimer to the responsive elements. This β-galactosidase activity is quantified at 540 nm by the conversion of the chromogenic substance chlorophenol red-β-D-galactopyranoside into chlorophenol red. The bioassay response is expressed as the absorbance at 540 nm divided by the optical density at 630 nm [(A540/A630) net ]. Positive signals in the Ah receptor assay were typically expressed as percentage equivalence to 200 nM benzo(a)pyrene, which arbitrarily corresponded to a bioassay response of 100%. Similarly, estrogenic activity of the samples was expressed as percentage equivalence to 6.96 nM 17α-ethynyl estradiol (EE2), which elicited a 100% response in the ER bioassay (De Boever et al. 2001) . To make sure that background signals from GI suspensions of soil or food matrices did not interfere with the detection of estrogenic signals in the bioassays, corrections were made in a set of negative control experiments by subtracting the response of a PAHcontaining digest from that from a blank digest without PAHs (see Supplemental Material available online at http://ehp.niehs.nih.gov/ docs/2004/7259/supplemental.pdf). The bioassays were performed in 96-well plates in which 10 µL of the test compounds was tested and incubated with 240 µL of the genetically modified yeast (optical density, 0.25 at 610 nm). Serial dilutions of the test compounds were made in dimethyl sulfoxide, which allowed generation of dose-response curves for doses (ordinate) versus activity (abscissa). The data were fitted by a four-parametric logistic model using the Marquardt-Levenberg algorithm (Sigmaplot 4.0; SPSS Inc., Chicago, IL, USA) (De Boever et al. 2001) .
PAH analysis. Sample treatment for and determination of PAHs were performed by the Environmental Research Centre (Erembodegem, Belgium). Briefly, PAHs from pellets were extracted by a 1:1 acetone:hexane mixture using an ASE 200 accelerated solvent extractor (Dionex, Sunnyvale, CA, USA). PAHs from supernatants were extracted with dichloromethane. Analysis of the PAH content in the extracts was performed according to a standardized method [U.S. Environmental Protection Agency (EPA) method 8270 (U.S. EPA 1996)] by gas chromatography coupled with mass spectrometry (GC-MS). We used a quadrupole mass spectrometer (Trace-MS; Fisons/Thermoquest, Antwerp, Belgium). The detection limit for the different PAH components was 0.2 µg/L, and the quantification limit was 0.4 µg/L. The extraction efficiency of the sample preparation step before PAH analysis was between 80 and 110%, as determined with reference soil CRM535 (Environmental Research Center, Erembodegem, Belgium).
LC-MS analysis. We performed LC-MS analysis of the samples for hydroxy-PAHs as previously described (Van de Wiele et al. (2004a) . The identity of hydroxy-PAH metabolites in the samples was confirmed by using synthetic standards of these metabolites and comparing the HPLC profiles from the colon digests with those from the standards. Briefly, all samples for LC-MS analysis were subjected to solid-phase extraction using PrepSep C 18 columns (250 mg). Sample volumes of 5 mL were loaded on the columns and washed with 10 mL Milli-Q water; the Article | Estrogenic PAH metabolites from colon microbiota Environmental Health Perspectives • VOLUME 113 | NUMBER 1 | January 2005 Figure 1 . Schematic representation of SHIME. Vessels 1-5 simulate conditions from the stomach, small intestine, colon ascendens, colon transversum, and colon descendens, respectively. 
Results and Discussion
Because of their moderate-to-high degree of aromaticity, we expected pure solutions of naphthalene, phenanthrene, pyrene, and benzo(a)pyrene to test positive in the Ah bioassay. Naphthalene (200 nM) displayed 0.4% benzo(a)pyrene equivalence, whereas 200 nM phenanthrene and 200 nM pyrene displayed 15.1 and 48.2% benzo(a)pyrene equivalence, respectively. PAH compounds are not estrogenic, and indeed, up to 16 µM of the four pure PAHs did not induce an estrogenic response in the estrogen bioassay. Similarly, separate stomach and small intestine digests of the four PAHs did not show a significant estrogen response (Figure 2 ). In contrast, PAHs from colon digests became estrogenic. Conversion of the percent EE2 equivalence values, shown in Figure 2 , to equivalent EE2 concentrations is as follows: for colon digests of 62.5 nM pyrene, 2.70 nM EE2 equivalence; for phenanthrene, 2.14 nM EE2 equivalence; for benzo(a)pyrene, 1.48 nM EE2 equivalence; and for naphthalene, 0.31 nM EE2 equivalence. This PAH bioactivation was only evident in colon digestion. This shows the selectivity of colon digestion toward an increase in estrogenicity, whereas no increased Ah response was detected, compared with stomach or small intestine digests. To make sure that the observed effects were not coming from the matrix background of the colon interacting with PAHs, we incubated PAHs in a heat-inactivated colon suspension. The removal of microbial activity markedly reduced the increase in estrogenic activity ( Figure 2 ). This finding indicates that the risk for PAH bioactivation along the GI tract is not exclusively associated with human biotransformation enzymes from the enterocytes in the small intestine epithelium and colonocytes in the large intestine epithelium (Autrup et al. 1978; De Kok and van Maanen 2000; Doherty and Charman 2002) , but that colon microbiota can also bioactivate PAHs. We then evaluated the significance of this process using lower, more realistic concentrations obtained from soil from a former urban playground contaminated with 49 ± 1.5 mg PAHs per kilogram soil (dry weight) by years of atmospheric deposition. Pica-afflicted children form the largest risk group for soil ingestion because of their unusual hand-mouth behavior and low body weight. Hence, we simulated the GI tract of a pica child, hypothetically ingesting 5 g soil/day. GC-MS analysis previously showed that the released PAH fraction from the soil matrix was highest in the stomach digest (18 ± 5.3 µg/L), followed by the small intestine digest (3 ± 1.1 µg/L) and the colon digest (2 ± 0.3 µg/L) ( Van de Wiele et al. 2004b) . This corresponded to a maximal Ah bioassay response for the stomach digest of 41 ± 2.9% benzo(a)pyrene equivalence; the small intestine, 27 ± 1.4%; and the colon, 22 ± 2.6% (Figure 3) . Based on the role of the human Ah receptor in the toxicity of specific aromatic hydrocarbons, these findings would normally indicate that the colon digest represents the lowest risk for PAH bioactivation. Surprisingly, the trend in estrogenic activity was the inverse of observed PAH release or Ah bioassay response. Similar to the estrogen bioassay results on pure PAHs, there was negligible induction of estrogenic activity in the stomach (0.6%) and small intestine (2.0%) digestion (Figure 4) . However, an average value of 20.1 ± 0.84% EE2 equivalence was observed in a colon digestion of the contaminated soil (Figure 4) . We infer that the PAH bioactivation potency from colon microbiota also occurs at lower and relevant concentrations for human exposure and that the presence of soil does not eliminate this potency.
Soil organic matter and nutritional fibers are known to lower the fraction of a contaminant that can be absorbed by the intestine (O'Neill et al. 1991; Oomen et al. 2000; van Schooten et al. 1990 ). This would theoretically lower the risk from ingested contaminants because bioactivation by human biotransformation enzymes will be reduced because of a lower bioavailability. To test this hypothesis, we compared the estrogenicity from colonincubated PAHs in the presence and absence of soil by calculating the bioactivation potency of the digests as estrogenicity/aromaticity. We divided-at equimolar concentrations-the percent EE2 equivalence of the different digests by their respective percent benzo(a)pyrene equivalence. At equimolar concentrations of 8.03 nmol PAH/L, this ratio was 0.93 for naphthalene, 2.16 for phenanthrene, 0.98 for pyrene, and 0.12 for benzo(a)pyrene, whereas the colon digest of the PAH-contaminated soil gave a ratio of 0.88, the same order of magnitude as the ratios for pure PAH compounds and one order of magnitude higher than the ratios for the stomach soil digest (0.016) or small intestine soil digest (0.077). 
PAH release Estrogenicity
These findings provide further evidence that the presence of a soil matrix does not eliminate the PAH bioactivation by colon microbiota and that the estrogenic potency of soil-derived PAHs does not significantly decrease if compared with pure PAHs.
PAH metabolites that typically have estrogenic properties are hydroxylated derivatives because of their structural similarity to natural estrogens (Fertuck et al. 2001; Hirose et al. 2001) . Hence, in the next step of the research, we screened with LC-MS for the presence of hydroxy-PAHs by analyzing the respective colon digests of 20 µmol/L pure PAH compounds. The identity of PAH metabolites was confirmed by comparing the HPLC profiles and MS spectra of the colon digests with those from chromatographic synthetic standards of several hydroxy-PAHs. The developed protocol had reasonably low detection limits for 1-OH naphthalene, 9-OH phenanthrene, 1-OH pyrene, and 7-OH benzo(a)pyrene (Table 1) ( Van de Wiele et al. 2004a) . No hydroxy-PAHs were detected upon stomach or small intestine incubations. From all colon digests, only the pyrene digest tested positive for a hydroxy-PAH metabolite, with 1-OH pyrene at a concentration of 2.5 µg/L (Table 1) . Glucuronidated or sulfated PAH conjugates are also typical biotransformation products from eukaryotic organisms (Cajthaml et al. 2002) . Because the concentration of fungi and yeasts in the colon suspension amounted to 4.3 ± 0.6 log colony forming units (CFU)/mL, we tested whether PAH conjugates were present in colon digests of pure PAH compounds. Glucuronidase and arylsulfatase typically cleave off glucuronic acid or sulfate groups from conjugated PAHs, regenerating the hydroxy-PAH metabolites (Cajthaml et al. 2002) . After incubating the extracts of the colon digests in the presence of glucuronidase (100 U/mL) and arylsulfatase (60 U/mL) for 6 hr at 37°C, we found higher concentrations of 1-OH pyrene (4.4 µg/L) and a new metabolite, 7-OH benzo(a)pyrene (1.9 µg/L). No hydroxy-PAHs were retrieved from inactivated colon samples. Although other hydroxy-PAHs may have formed than those tested during LC-MS analysis, these analytical data show that PAH bioactivation by colon microbiota may result from hydroxy-PAH metabolites.
The formation of hydroxy-PAH metabolites and especially the increased estrogenicity by human colon microbiota bring up two questions: are the observed transformations plausible for the in vivo human GI tract, and to what extent can bioactive PAH metabolites contribute to the total risk from oral PAH exposure? To answer the first question, literature shows that resident gut microbiota may influence xenobiotic metabolism from the intestinal epithelium (Hooper et al. 2001) . Additionally, microbial glucuronidase activity in the intestine sometimes cleaves off glucuronic acid groups from excreted human conjugated metabolites, thus regenerating the more bioactive hydroxylated intermediates (Aura et al. 2002) . These reports describe indirect effects of intestinal microbiota toward xenobiotic metabolism. However, our findings indicate a direct metabolism effect of human colon microbiota toward PAH parent compounds, because the in vitro approach used in the present study eliminated possible interferences by intestinal epithelium enzymes. The observed biotransformation and bioactivation reactions originate from a microbial community that resembles that of the in vivo intestinal lumen both in composition and in metabolic activity. Rather than containing the less active microbiota from fecal matter, the microbial community from the used in vitro method is more representative of the different parts of the human colon (Molly et al. 1993) .
As suggested by the LC-MS results, the colon microbiota formed hydroxy-PAH metabolites, which may seem unlikely because this oxidative step would occur in an anaerobic environment, as shown by redox potential values from the colon suspension, which varied between -180 mV and -230 mV. These values are well within the range of -145 mV to -250 mV reported for the colon in vivo (Bowler et al. 2001; Chourasia and Jain 2003) . Yet, oxidative reactions by intestinal bacteria from humans, mice, and rats have been described for the conversion of 2-amino-3-methylimidazo[4,5-f ]quinoline to its reportedly mutagenic 7-keto derivative (Rumney et al. 1993) . Additionally, Enterococcus faecalis even performs aromatic hydroxylation reactions in the intestine in vivo (Huycke and Moore 2002) . It is therefore not unlikely that intestinal microbiota may hydroxylate PAHs, also given the fact that anaerobic PAH hydroxylation has been reported by microorganisms, albeit in sediments (Karthikeyan and Bhandari 2001) . These studies on oxidative reactions by intestinal microbiota and anaerobic PAH biotransformations may thus support our findings, which need further study to identify which microorganisms bioactivate PAHs.
To answer the second question concerning the contribution of the observed effects to the total risk from PAH ingestion, further research is warranted. Yet, microbial PAH bioactivation to estrogenic metabolites may constitute an increased health risk when the human body is orally exposed to contaminated soils. Human colon epithelium is 20% more permeable to 17β-estradiol than is the human small intestine epithelium (van der Bijl and van Eyk 2003) and also has a higher permeability to hydrophobic compounds in general (Ungell et al. 1998) . PAH metabolites with structures resembling steroidal hormones may thus exhibit weak estrogenic or antiestrogenic activity in vivo (Ariese et al. 2001) . Because PAHs that reach the colon will be biotransformed by colon microbiota, we conclude that, in the in vivo situation, the colonic epitheliumwhich has ERs-may be subjected to hazardous effects from microbial PAH metabolites. The equivalent EE2 response of 20% for the colon-incubated environmental sample (Figure 4) indicates that the observed activation of the human ER is significant. Still, it must be kept in mind that a positive response in ER-reporter gene assays such as that from the present study does not necessarily predict endogenous transcription (Gozgit et al. 2004 ). Gozgit et al. (2004) noted that several PAHs induced activity in ER-reporter gene assays but that these PAHs did not up-regulate estrogen-responsive genes. The authors concluded that ER-reporter gene assays may detect concentrations of toxicants that are not physiologically active. In light of these recent findings, the estrogenic response from microbial PAH bioactivation in this study needs careful interpretation. However, the finding of 1-OH pyrene and 7-OH benzo(a)pyrene as metabolites from human colon microbiota is something that is not anticipated from current scientific knowledge or risk assessment studies. Comparison of our findings from active to those from inactivated colon microbiota shows that the microbial bioactivation potency is a factor of 12 higher than would be currently expected in risk calculations. Moreover, the time during which bioactive hydroxy-PAHs could react with colonocytes is also considerably longer (up to 72 hr) than the residence time in human enterocytes or hepatocytes (6 hr maximum). Additionally, if taken up by colonocytes, the hydroxy-PAHs are typical metabolites that are more easily metabolized by human biotransformation enzymes to, for example, potent carcinogens such as benzo(a)pyrene-r7,t8-dihydrodiolt9,10-epoxide (Kim et al. 1998) . Clearly, these literature reports on human PAH metabolism and our findings of PAH bioactivation by colon microbiota indicate the importance of conducting future work in which the relative importance of the human bioactivation Article | Estrogenic PAH metabolites from colon microbiota Environmental Health Perspectives • VOLUME 113 | NUMBER 1 | January 2005 processes versus the microbial bioactivation processes should be compared.
Conclusion
Our results reveal that human colon microbiota can directly bioactivate PAHs, a potency that has not been reported before. As indicated by the analysis of a PAH-contaminated environmental sample, we also show that the presence of soil does not eliminate this microbial bioactivation potency. We therefore conclude that risk calculations that are based solely on human biotransformation enzymes may underestimate the risk from ingested aromatic contaminants because it does not consider the bioactivation processes described here.
